In a Virtual World, Where Are the Walls of the House? The New Outsourcing
Katya Tsaioun, President, Apredica speaking at Pharma Outsourcing Congress 2011
Clinical Trials Utilising Radioactivity in Support of Drug Development
Stephen Madden, Head, Metabolism and Pharmacokinetics, Charles River speaking at ADMET Europe 2011
Selecting the right CMO partner
David Downey, VP, Commercial Operations, Almac Group speaking at Pharma Outsourcing Congress 2011
How to Obtain a Solid Track Record in Medicinal Chemistry Research Services
Bruno Giethlen, Chief Scientific Officer, Prestwick Chemicals speaking at Pharma Outsourcing Congress 2011
Biomarkers of Metabolic Syndrome in Clinical Trials
This will discuss the latest developments in biomarkers for metabolic syndrome. The topics will include: 1) Pre-analytical and analytical concerns regarding gut and incretin hormones, 2) dysfunctional HDL biomarkers in metabolic syndrome, and 3) kidney injury markers and their usefulness in diabetic nephropathy.
Smarter Regulation: the Key to Radical Transformation of the Pharmaceutical Industry
Joyce Tait, Professor, University of Edinburgh, speaking at the Pharma Outsourcing Congress 2010.
Legal Aspects of Outsourcing Drug Discovery
Hiroshi Sheraton, Partner, McDermott Will & Emery UK, speaking at the Pharma Outsourcing Congress 2010.
A Quality Assurance Perspective on Selecting and Monitoring Contract Research Organizations (CROs)
Thomas Ott, Pharmaceutical Consultant, speaking at the Pharma Outsourcing Congress 2010.
Education and Training in Clinical Research: What are the Best Outsourcing Strategies?
Heinrich Klech, Professor/CEO, Vienna School of Clinical Research, speaking at the Pharma Outsourcing Congress 2010.
|<< || 1 2 3 || >>|
|Showing Results 11 - 20 of 22|